SeaStar Medical sees 247% revenue increase in Q3 2026
SeaStar Medical exceeded expectations with a 247% surge in net revenue driven by the adoption of its QUELIMMUNE pediatric therapy, alongside progress in its pivotal NEUTRALIZE-AKI clinical trial.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed